Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
2.390
+0.070 (3.02%)
At close: Nov 4, 2024, 4:00 PM
2.400
+0.010 (0.42%)
After-hours: Nov 4, 2024, 4:34 PM EST
Oramed Pharmaceuticals Revenue
In the year 2023, Oramed Pharmaceuticals had annual revenue of $1.34M, down -50.43%.
Revenue (ttm)
$1.34M
Revenue Growth
-50.43%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
97.44M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.34M | -1.36M | -50.43% |
Dec 31, 2022 | 2.70M | -9.00K | -0.33% |
Dec 31, 2021 | 2.71M | 9.00K | 0.33% |
Aug 31, 2021 | 2.70M | -9.00K | -0.33% |
Dec 31, 2020 | 2.71M | 2.00K | 0.07% |
Aug 31, 2020 | Pro | Pro | Pro |
Aug 31, 2019 | Pro | Pro | Pro |
Aug 31, 2018 | Pro | Pro | Pro |
Aug 31, 2017 | Pro | Pro | Pro |
Aug 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Assertio Holdings | 132.19M |
OptimizeRx | 83.20M |
MDxHealth | 80.74M |
Cidara Therapeutics | 53.87M |
Protalix BioTherapeutics | 38.05M |
InflaRx | 113.02K |
ORMP News
- 4 weeks ago - Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - PRNewsWire
- 4 months ago - Oramed Letter to Shareholders - PRNewsWire
- 4 months ago - Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock - PRNewsWire
- 1 year ago - Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company - PRNewsWire
- 1 year ago - Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally - PRNewsWire
- 1 year ago - Oramed to Present at the 83rd American Diabetes Association Conference - PRNewsWire
- 1 year ago - Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit - PRNewsWire
- 1 year ago - Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China - PRNewsWire